Menu

GOVPH

HTAC'S PRELIMINARY LIST OF PRIORITY TOPICS FOR HTA 2022
Extension of Deadline for Topic Nomination Submissions
HTAC Calls for Topic Nomination
HTA Philippines Facebook Page
HTA and the COVID-19 pandemic
DOH Releases New Implementing Guidelines on HTA
DOH holds first HTA public consultation
DOH holds HTA Workshop and Policy Symposium
Towards UHC: DOH and PhilHealth gear up for HTA
DOH holds high-level forum to accelerate HTA
DOH convenes local experts to create HTAC

HTAC Recommend for Potassium Citrate for inclusion in the PNF
HTAC Recommend for Tocilizumab for inclusion in the PNF
HTAC RECOMMENDATION: COVID-19 VACCINE COVOVAX
HTAC RECOMMENDATION: COVID-19 VACCINE SPUTNIK V
HTAC RECOMMENDATION: COVID-19 VACCINE SINOPHARM
HTAC RECOMMENDATION: COVID-19 VACCINE COVAXIN
HTAC Recommends COVID-19 Vaccine Booster and Additional dose: Guidance and Conditions on Implementation
HTAC GUIDANCE: COVID-19 VACCINATION AMONG THE ADOLESCENT POPULATION
GABAY NG HTAC PARA SA PAGBABAKUNA NG KABATAANG FILIPINO
COVID-19 VACCINES EVIDENCE SUMMARY HTAC PRESS RELEASE
COVID-19 VACINE MODERNA GUIDANCE FOR THE GENERAL PUBLIC
COVID-19 VACINE MODERNA GUIDANCE FOR HEALTH CARE PROVIDERS
COVID-19 VACINE JANSSEN GUIDANCE FOR THE GENERAL PUBLIC
COVID-19 VACINE JANSSEN GUIDANCE FOR HEALTH CARE PROVIDERS
COVID-19 VACINE GAMALEYA GUIDANCE FOR THE GENERAL PUBLIC
COVID-19 VACINE GAMALEYA GUIDANCE FOR HEALTH CARE PROVIDERS
COVID-19 VACCINE SINOVAC GUIDANCE FOR THE GENERAL PUBLIC
COVID-19 VACCINE SINOVAC GUIDANCE FOR HEALTH CARE PROVIDERS
COVID-19 VACCINE ASTRAZENECA GUIDANCE FOR PATIENTS
PFIZER-BIONTECH COVID-19 VACCINE GUIDANCE FOR PATIENTS
COVID-19 VACCINE ASTRAZENECA GUIDANCE FOR HEALTH CARE PROVIDERS
HTAC recommends COVID-19 Vaccine AstraZeneca under emergency use for reducing COVID-19 risk in persons aged 18 and older
PFIZER-BIONTECH COVID-19 VACCINE for health care providers
HTAC recommends Pfizer-BioNTech COVID-19 Vaccine under emergency use for reducing COVID-19 risk in persons aged 16 and older
HTA Philippines publishes HTAC Evaluation Framework for COVID-19 Vaccines
HTAC recommends pooled RT-PCR testing to monitor COVID transmission in populations with low case numbers
HTAC recommends Rapid Antigen Test kits for symptomatic COVID-19, contact tracing, managing outbreaks and supplementing lack of RT-PCR confirmatory testing
HTAC releases guidance for ECMO, notes insufficient evidence to recommend use

EVENTS AND PRESS RELEASES

[Presentation slides + Question and answers] HTA Philippines Virtual Public Consultation for the Preliminary Priority List for HTA 2022

HTAC’S PRELIMINARY LIST OF PRIORITY TOPICS FOR HTA 2022 UNDER THE GENERAL TRACK

COVID-19 Vaccines Evidence Summary HTAC Press Release

CALL FOR INTERESTED PARTIES

READ MORE

HTAC RECOMMENDATIONS

HTAC recommendation for eribulin in the treatment of soft tissue sarcoma patients with previous treatment of two other chemotherapeutic agents for metastatic disease

HTAC recommendation for the non-inclusion of rituximab 1400 mg/ 11.7 mL solution for subcutaneous (SC) injection for the treatment of non-Hodgkin’s lymphoma

HTAC recommendation on the reinclusion of vasopressin in the PNF

Emtricitabine + Tenofovir Disoproxil Fumarate fixed-dose combination as Oral Pre-Exposure Prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-infection

READ MORE

STAKEHOLDER INVOLVEMENT

HTAC PRELIMINARY RECOMMENDATION ON abiraterone acetate(250mg tablet) and enzalutamide (40mg soft gel capsule)

DEPARTMENT CIRCULAR No. 2022 – 0491: Nomination to the Health Technology Assessment Council (HTAC) Core Committee and Subcommittee Members

[ADVISORY] DRAFT GUIDELINES ON THE APPLICATION OF PHILIPPINE SOCIAL VALUES ON HEALTH TECHNOLOGY ASSESSMENT for public consultation from 21 September to 05 October 2022

updates from international HTA agencies

CADTH Reimbursement Reviews Process in Brief

NEWS BRIEFS

[Presentation slides + Question and answers] HTA Philippines Virtual Public Consultation for the Preliminary Priority List for HTA 2022

HTAC’S PRELIMINARY LIST OF PRIORITY TOPICS FOR HTA 2022 UNDER THE GENERAL TRACK

HTAC recommendation for the non-inclusion of rituximab 1400 mg/ 11.7 mL solution for subcutaneous (SC) injection for the treatment of non-Hodgkin’s lymphoma

HTAC Recommendation on the Second Booster of COVID-19 vaccines for the prevention of COVID-19 among individuals aged 50 years old and older and individuals with comorbidities aged 18 to 49 years old

HTAC Guidance: Self-Administered Antigen Test Kits (SAAgT)

CONTACT US

Business Hours:

8:00 a.m. to 5:00 p.m. (GMT+8) | Monday to Friday

Email:

hta@doh.gov.ph

Telephone:

8-875-7734 ext. 260

Address:

4th Floor, Philippine Blood Disease and Transfusion Center, Lung Center Compound, Quezon Avenue, Diliman, Quezon City